KFBIO and Huawei Strengthen Strategic Partnership in Digital Pathology

KFBIO and Huawei Hold Digital Pathology Cooperation and Exchange Meeting

On June 20, 2022, KFBIO and Huawei successfully held a Digital Pathology Cooperation and Exchange Meeting at KFBIO headquarters. The meeting brought together senior leaders from both companies. Attendees included Liu Bingxian, Chairman and General Manager of KFBIO, and Zhou Yuefeng, Vice President of Huawei and President of Huawei’s Data Storage Product Line. The event marked an important milestone in strengthening cooperation between KFBIO and Huawei in the field of digital pathology.

Exploring KFBIO’s Digital Pathology Innovations

Before the meeting, Gui Kun, Deputy General Manager of KFBIO, guided Huawei representatives through the KFBIO Digital Pathology Exhibition Hall. During the visit, he introduced KFBIO’s development history and business achievements. He also highlighted the company’s research capabilities and technological innovations. The exhibition showcased KFBIO’s expertise in digital pathology solutions. Visitors gained insights into the company’s products, technologies, and industry applications.

Advancing Digital Pathology Through Strategic Collaboration

During the meeting, Bai Shuqing, Medical Director of Huawei’s Data Storage Product Line, introduced Huawei’s advanced data storage solutions and their practical applications in the medical industry. Following this, Gui Kun elaborated on KFBIO’s integrated digital pathology solutions, which include digital pathology slide scanners, pathology AI, pathology information systems, remote consultation platforms, and third-party pathology labs.

The exchange meeting provided a platform for in-depth discussions on future cooperation.Both parties explored opportunities in:

• Digital pathology technology research and development
• Data storage and infrastructure solutions
• Market expansion strategies
• Talent development and professional training
• Digital healthcare innovation

The discussions reflected a shared vision for accelerating digital transformation in pathology.

Building a Benchmark for Digital Pathology in China

KFBIO and Huawei agreed to deepen their strategic partnership. Both companies will continue strengthening collaboration across technology, marketing, and industry development. By combining their expertise, KFBIO and Huawei aim to explore new opportunities in digital pathology. The partnership is expected to support the development of modern pathology departments and promote healthcare digitalization across China. Together, KFBIO and Huawei are committed to establishing a benchmark model for digital pathology department construction and innovation.

This partnership signifies a new phase in KFBIO-Huawei collaboration, with reinforced efforts in technology R&D, marketing, and talent training. Together, KFBIO and Huawei will explore new possibilities in digital pathology and strive to set a benchmark for digital pathology department construction in China.